Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 1
2007 2
2008 1
2009 1
2011 1
2013 1
2015 1
2016 2
2018 3
2019 5
2020 7
2021 4
2022 5
2023 4
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

36 results

Results by year

Filters applied: . Clear all
Page 1
Baricitinib Liposomes as a New Approach for the Treatment of Sjögren's Syndrome.
Garrós N, Mallandrich M, Beirampour N, Mohammadi R, Domènech Ò, Rodríguez-Lagunas MJ, Clares B, Colom H. Garrós N, et al. Pharmaceutics. 2022 Sep 7;14(9):1895. doi: 10.3390/pharmaceutics14091895. Pharmaceutics. 2022. PMID: 36145642 Free PMC article.
Two liposomal formulations were prepared with different lipids: (i) L-alpha-phosphatidylcholine (Lalpha-PC) and (ii) a combination of lipids 1-palmitoyl-2-oleoyl-phosphatidylethanolamine: s1-Palmitoyl-2-oleoyl-sn-glycerol-3-phosphoglycerol (3:1, mol/mol) (POPE:POPG), and t …
Two liposomal formulations were prepared with different lipids: (i) L-alpha-phosphatidylcholine (Lalpha-PC) and (ii) a combination of lipids …
Constraints on the evolution of toxin-resistant Na,K-ATPases have limited dependence on sequence divergence.
Mohammadi S, Herrera-Álvarez S, Yang L, Rodríguez-Ordoñez MDP, Zhang K, Storz JF, Dobler S, Crawford AJ, Andolfatto P. Mohammadi S, et al. PLoS Genet. 2022 Aug 16;18(8):e1010323. doi: 10.1371/journal.pgen.1010323. eCollection 2022 Aug. PLoS Genet. 2022. PMID: 35972957 Free PMC article.
We propose that dependence on a limited number sites may account for the observation of convergent CTS resistance substitutions observed among taxa with highly divergent Na,K-ATPases (See S1 Text for Spanish translation)....
We propose that dependence on a limited number sites may account for the observation of convergent CTS resistance substitutions observed amo …
Casirivimab + imdevimab accelerates symptom resolution linked to improved COVID-19 outcomes across susceptible antibody and risk profiles.
Li D, Xu M, Hooper AT, Rofail D, Mohammadi KA, Chen Y, Ali S, Norton T, Weinreich DM, Musser BJ, Hamilton JD, Geba GP. Li D, et al. Sci Rep. 2023 Aug 7;13(1):12784. doi: 10.1038/s41598-023-39681-7. Sci Rep. 2023. PMID: 37550377 Free PMC article. Clinical Trial.
In a placebo-controlled study of casirivimab and imdevimab (CAS + IMD) in persons at high risk of severe coronavirus disease 2019 (COVID-19; n = 3816), evolution of individual symptoms was assessed for resolution patterns across risk factors, and baseline SARS-CoV-2-specific anti …
In a placebo-controlled study of casirivimab and imdevimab (CAS + IMD) in persons at high risk of severe coronavirus disease 2019 (COVID-19; …
36 results